Hi, I got this kind of drop many times with PEG and MPD conditions. It will be very interesting to study this.
Pankaj On Tue, Jan 6, 2015 at 7:30 AM, Hargreaves, David < david.hargrea...@astrazeneca.com> wrote: > On the face of it, I wouldn’t get overly excited by the drop. However, > I’ve been underwhelmed and wrong before. If you’ve got access to a > synchrotron beamline that can shoot the material in-situ it might be a good > experiment to try. > > Best of luck, > > Dave > > > > *Dr. David Hargreaves* > > Associate Principal Scientist > > _____________________________________________________________________ > > AstraZeneca > > Discovery Sciences, Structure & Biophysics > > Dr David Hargreaves. > > OfficeR1-09/Lab FL54 > > AstraZeneca Darwin Building > > Unit 310 > > Cambridge Science Park > > Milton Road > > Cambridge > > CB4 0WG > > > > telephone: +441223223546 > > mobile: 07525 742054 > > > > David.Hargreaves @astrazeneca.com <name.surn...@astrazeneca.com> > > > > Please consider the environment before printing this e-mail > > > > *From:* CCP4 bulletin board [mailto:CCP4BB@JISCMAIL.AC.UK] *On Behalf Of *P > Silva > *Sent:* 05 January 2015 19:12 > *To:* CCP4BB@JISCMAIL.AC.UK > *Subject:* [ccp4bb] Crystallization issue > > > > Hi everyone, > > > > Sorry for the non related crystallization question. In a crystallization > screening (20ºC) I got in 70% of the drops some fibrils/gel (see figure > below) which I do not know how to interpret. Has anyone got the same kind > of behavior in crystallization screenings? It could be related with the > stability of the protein (salt concentration, pH,...)? > > The buffer of the protein is 20mM Tris pH 7.5, 150mM NaCl. > > > > Thanks in advance > ------------------------------ > > AstraZeneca UK Limited is a company incorporated in England and Wales with > registered number: 03674842 and a registered office at 2 Kingdom Street, > London, W2 6BD. > > *Confidentiality Notice: *This message is private and may contain > confidential, proprietary and legally privileged information. If you have > received this message in error, please notify us and remove it from your > system and note that you must not copy, distribute or take any action in > reliance on it. Any unauthorised use or disclosure of the contents of this > message is not permitted and may be unlawful. > > *Disclaimer:* Email messages may be subject to delays, interception, > non-delivery and unauthorised alterations. Therefore, information expressed > in this message is not given or endorsed by AstraZeneca UK Limited unless > otherwise notified by an authorised representative independent of this > message. No contractual relationship is created by this message by any > person unless specifically indicated by agreement in writing other than > email. > > *Monitoring: *AstraZeneca UK Limited may monitor email traffic data and > content for the purposes of the prevention and detection of crime, ensuring > the security of our computer systems and checking compliance with our Code > of Conduct and policies. > -- Pankaj Kumar, PhD Gyanu Lemichhane lab <http://webhost.nts.jhu.edu/gl/> Centre for Tuberculosis Research Lab Department of Infectious Disease Johns Hopkins University School of Medicine 725 N. Wolfe St. Baltimore, MD 21205-2185 Lab phone: (410) 955-3967 pkuma...@jhmi.edu pkuma...@commsmail.johnshopkins.edu http://pankajimtech.webs.com
